Skip to search formSkip to main contentSkip to account menu

GC1118

Known as: Anti-EGFR Monoclonal Antibody GC1118 
A recombinant, human monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Upon… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Antibodies, Monoclonal, Humanized
NCIt Antineoplastic Agent Terminologyantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Phase Ib/IIa study of GC1118 in combination with irinotecan or FOLFIRI in patients with metastatic solid tumors.
3592Background: GC1118 is a novel anti-EGFR monoclonal antibody which has a unique binding epitope and superior ligand inhibition… 
2018
2018
Abstract 3496: GC1118, a novel anti-EGFR andtibody, shows more potent antitumor activity regardless of KRAS mutation or high-affinity lignad stimulation compared with cetuximab in gastric cancer
Background: EGFR overexpression in gastric cancer (GC) has been reported in about 30% of patients. However, cetuximab and… 
2017
2017
Use of a Target‐Mediated Drug Disposition Model to Predict the Human Pharmacokinetics and Target Occupancy of GC1118, an Anti‐epidermal Growth Factor Receptor Antibody
GC1118 is an anti‐epidermal growth factor receptor (EGFR) monoclonal antibody that is currently under clinical development. In… 
2016
2016
A first-in-human phase 1 study of GC1118, a novel monoclonal antibody inhibiting epidermal growth factor receptor (EGFR), in patients with advanced solid tumors.
2521Background: GC1118 is a novel anti-EGFR monoclonal antibody and has unique binding epitopes and affinity. We conduct a first… 
2016
2016
Abstract LB-114: GC1118, a new anti-EGFR antibody overcome acquired resistance to cetuximab in colorectal cancer xenograft model
Purpose: Anti-epidermal growth factor receptor (EGFR) antibodies such as cetuximab and panitumumab are widely used to treat… 
2016
2016
EGFR targeting antibody of GC1118 effects in Colorectal cancer with KRAS mutation
2016
2016
GC1118, a new EGFR targeting antibody, in patient derived xenograft model of KRAS mutation colorectal cancer and EGFR viii expressed glioblastoma
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)